Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Heuser

Showing results (101-110 of 114) with videos related to

Pageof 12
Sort By:
Pharmacopsychiatry|September 3, 2008
Standardized remission criteria in schizophrenia: descriptive validity and comparability with previously used outcome measuresM Jäger, T Messer, G Laux, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|December 27, 2014
What are depressive symptoms in acutely ill patients with schizophrenia spectrum disorder?R Schennach, M Riedel, M Obermeier, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|May 1, 2012
Insight in schizophrenia-course and predictors during the acute treatment phase of patients suffering from a schizophrenia spectrum disorderR Schennach, S Meyer, F Seemüller, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|May 4, 2010
Response and remission of subjective well-being in patients suffering from schizophrenia spectrum disordersR Schennach-Wolff, F Seemüller, M Obermeier, et al.
The Journal of Nutrition, Health & Aging|June 5, 2012
A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCIO Peters, D Lorenz, A Fesche, et al.
Acta Psychiatrica Scandinavica|November 3, 2009
Outcome of suicidal patients with schizophrenia: results from a naturalistic studyR Schennach-Wolff, M Jäger, F Seemüller, et al.
Acta Psychiatrica Scandinavica|October 30, 2010
Evaluating depressive symptoms and their impact on outcome in schizophrenia applying the Calgary Depression ScaleR Schennach-Wolff, M Obermeier, F Seemüller, et al.
Pharmacopsychiatry|October 8, 2010
A critical analysis and discussion of the appropriateness of the schizophrenia consensus remission criteria in clinical pharmaceutical trialsR Schennach-Wolff, H-J Möller, M Jäger, et al.
Psychological Medicine|January 8, 2008
Vagus nerve stimulation for depression: efficacy and safety in a European studyT E Schlaepfer, C Frick, A Zobel, et al.
The Journal of Nutrition, Health & Aging|March 6, 2009
Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessmentK Blennow, G De Meyer, O Hansson, et al.
Pageof 12

Showing results (101-110 of 114) with videos related to

Sort By:
Pageof 12
Pharmacopsychiatry|September 3, 2008
Standardized remission criteria in schizophrenia: descriptive validity and comparability with previously used outcome measuresM Jäger, T Messer, G Laux, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|December 27, 2014
What are depressive symptoms in acutely ill patients with schizophrenia spectrum disorder?R Schennach, M Riedel, M Obermeier, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|May 1, 2012
Insight in schizophrenia-course and predictors during the acute treatment phase of patients suffering from a schizophrenia spectrum disorderR Schennach, S Meyer, F Seemüller, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|May 4, 2010
Response and remission of subjective well-being in patients suffering from schizophrenia spectrum disordersR Schennach-Wolff, F Seemüller, M Obermeier, et al.
The Journal of Nutrition, Health & Aging|June 5, 2012
A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCIO Peters, D Lorenz, A Fesche, et al.
Acta Psychiatrica Scandinavica|November 3, 2009
Outcome of suicidal patients with schizophrenia: results from a naturalistic studyR Schennach-Wolff, M Jäger, F Seemüller, et al.
Acta Psychiatrica Scandinavica|October 30, 2010
Evaluating depressive symptoms and their impact on outcome in schizophrenia applying the Calgary Depression ScaleR Schennach-Wolff, M Obermeier, F Seemüller, et al.
Pharmacopsychiatry|October 8, 2010
A critical analysis and discussion of the appropriateness of the schizophrenia consensus remission criteria in clinical pharmaceutical trialsR Schennach-Wolff, H-J Möller, M Jäger, et al.
Psychological Medicine|January 8, 2008
Vagus nerve stimulation for depression: efficacy and safety in a European studyT E Schlaepfer, C Frick, A Zobel, et al.
The Journal of Nutrition, Health & Aging|March 6, 2009
Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessmentK Blennow, G De Meyer, O Hansson, et al.
Pageof 12